| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-83 |
Sentence |
denotes |
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. |
| T1 |
0-83 |
Sentence |
denotes |
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. |
| TextSentencer_T2 |
84-360 |
Sentence |
denotes |
Hypoxia occurs frequently in human cancers and induces adaptive changes in cell metabolism that include a switch from oxidative phosphorylation to glycolysis, increased glycogen synthesis, and a switch from glucose to glutamine as the major substrate for fatty acid synthesis. |
| T2 |
84-360 |
Sentence |
denotes |
Hypoxia occurs frequently in human cancers and induces adaptive changes in cell metabolism that include a switch from oxidative phosphorylation to glycolysis, increased glycogen synthesis, and a switch from glucose to glutamine as the major substrate for fatty acid synthesis. |
| TextSentencer_T3 |
361-524 |
Sentence |
denotes |
This broad metabolic reprogramming is coordinated at the transcriptional level by HIF-1, which functions as a master regulator to balance oxygen supply and demand. |
| T3 |
361-524 |
Sentence |
denotes |
This broad metabolic reprogramming is coordinated at the transcriptional level by HIF-1, which functions as a master regulator to balance oxygen supply and demand. |
| TextSentencer_T4 |
525-771 |
Sentence |
denotes |
HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy. |
| T4 |
525-771 |
Sentence |
denotes |
HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy. |
| TextSentencer_T5 |
772-915 |
Sentence |
denotes |
Inhibitors of HIF-1 or metabolic enzymes may impair the metabolic flexibility of cancer cells and make them more sensitive to anticancer drugs. |
| T5 |
772-915 |
Sentence |
denotes |
Inhibitors of HIF-1 or metabolic enzymes may impair the metabolic flexibility of cancer cells and make them more sensitive to anticancer drugs. |